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Hyaluronan (HA), the only non-sulfated glycosaminogly-
can, is involved in morphogenesis, wound healing, inflamma-
tion, angiogenesis, and cancer. In mammals, HA is synthe-
sized by three homologous HA synthases, HAS1, HAS2, and
HAS3, that polymerize the HA chain using UDP-glucuronic
acid and UDP-N-acetylglucosamine as precursors. Since the
amount of HA is critical in several pathophysiological condi-
tions, we developed a non-radioactive assay formeasuring the
activity of HA synthases (HASs) in eukaryotic cells and
addressed the question of HAS activity during intracellular
protein trafficking. We prepared three cellular fractions:
plasma membrane, cytosol (containing membrane proteins
mainly from the endoplasmic reticulum and Golgi), and
nuclei. After incubation with UDP-sugar precursors, newly
synthesized HAwas quantified by polyacrylamide gel electro-
phoresis of fluorophore-labeled saccharides and high per-
formance liquid chromatography. This new method meas-
ured HAS activity not only in the plasma membrane fraction
but also in the cytosolic membranes. This new technique was
used to evaluate the effects of 4-methylumbeliferone, phor-
bol 12-myristate 13-acetate, interleukin 1, platelet-derived
growth factor BB, and tunicamycin on HAS activities. We
found that HAS activity can be modulated by post-transla-
tional modification, such as phosphorylation and N-glycosy-
lation. Interestingly, we detected a significant increase in
HAS activity in the cytosolic membrane fraction after tunica-
mycin treatment. Since this compound is known to induce
HA cable structures, this result links HAS activity alteration
with the capability of the cell to promote HA cable formation.
Hyaluronan (HA)3 is the only non-sulfated linear polymer
belonging to the family of glycosaminoglycans (GAGs). HA is
an unbranched polymer of alternating GlcNAc and GlcUA res-
idues linked by alternate (134) and (133) bonds. Native
HA is typically larger than other GAGs, reaching molecular
mass values between 106 and 107 Da.
HA is a major component of extracellular matrices and in
pericellular spaces, particularly in tissues with rapid cell prolif-
eration and cell migration (1). Through interactions with cell
surface receptors, notably CD44 and RHAMM (receptor for
HA-mediated motility), HA has important roles in regulating
cell behavior, including signal transduction, cell adhesion, pro-
liferation, migration, and differentiation (2). Recently, novel
interactions involving HA and Toll-like receptors 4 and 2 have
been described that have important roles in inflammation (3, 4).
Moreover, HA has been implicated in morphogenesis (5–8),
wound healing (9), angiogenesis (10), malignancies, cancer
growth, and tumor invasion (11).
In mammals, HA is normally synthesized at the plasma
membrane and extruded directly into the extracellular space by
three isoforms of HA synthases (HASs), HAS1, -2, and -3. The
threeHAS isoforms differ in tissue distribution, regulation, and
enzymatic properties (12); nevertheless, they are similar in
amino acid sequences and molecular structures.
HA biosynthesis is under the control of a wide variety of
cytokines and growth factors (13). The changes inHA synthesis
can be related to HAS mRNA expression (14), to availability of
the UDP-sugar precursors (15, 16), or to modulation by phos-
phorylation of HAS (17–19) in response to cytokines and
growth factors. Moreover, HA chain synthesis can be con-
trolled by additional mechanisms, such as cell type, intracellu-
lar environment, or HAS accessory proteins (20). Cultures of
smooth muscle cells isolated from human colon increase syn-
thesis of HA after treatment with a viral mimetic molecule
(poly(I-C)) (21). The HA is organized into novel cable-like
structures, and their synthesis may be initiated in the perinu-
clear and/or the endoplasmic reticulum (ER) membranes (22).
Furthermore, HA interstitial deposition is correlated with
inflammatory processes (23, 24) in which HA-CD44 interac-
tions stimulate leukocyte adhesion in order to generate an
inflammatory response (25).
Cytokines and growth factors, such as IL-1 and platelet-
derived growth factor BB (PDGF-BB), as well as 4-methylum-
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beliferone (4-MU) and the tumor promoter phorbol 12-myris-
tate 13-acetate (PMA), alsomodulate HA synthesis (26–29). In
order to elucidate how these different effectors affect HAS
activity, it is important to purify and solubilize the HAS
enzymes as previously underlined in studies on eukaryotic cell
lines (30). In this context, Itano and Kimata (31) used a mam-
malian transient expression system to characterize the three
different HAS isoforms in either cells or cellular membrane
extracts. On the other hand, Spicer (32) described three rela-
tively simple procedures for the detection ofHA synthase activ-
ity in cultured mammalian cell lines. In all of these studies, the
enzyme activity was measured by incubating cellular mem-
brane extracts with radiolabeled UDP-sugar precursors, and
the final analysis of the productswas done by liquid scintillation
counting. Various other strategies and methods can be used to
determine the HA biosynthetic capacity of cells, although they
are always based on the use of radiolabeled UDP-sugar precur-
sors (33–35).
In our previous studies, we described methods of polyacryl-
amide gel electrophoresis of fluorophore-labeled saccharides
(PAGEFS) and high performance liquid chromatography
(HPLC) for the analysis of disaccharides derived from HA and
chondroitin sulfate (33–38). In order to improve the sensitivity
of thismethod, a derivatizationwith 2-aminoacridone (AMAC)
was done, followed by fluorescence detection (39). In this study,
wemodified thismethod to address the question of localization
of HAS activity during intracellular trafficking, since HA has
been detected inside cells in previous studies (40–42). This
new non-radioactivemethod was used to quantify HAS activity
on cell membranes fractionated by sucrose gradient methods.
To test the robustness of our approach, we analyzed the effect
of 4-MU, PMA, IL-1, PDGF-BB, and tunicamycin on cell cul-
tures. In particular, we found that tunicamycin induced an
increase of HA synthesis in both plasma and internal cell mem-
branes in EVC cells, whereas it increased HA synthesis only in
the internal cell membranes in the OVCAR-3 cells. The results
suggest that post-translational modulation of HAS activity is
responsible for the increased HA synthesis inside the cells.
Moreover, since tunicamycin induced HA cable structures in
theOVCAR-3 cells, we correlated the altered intracellular HAS
activity with the capability to promote HA cable formation.
EXPERIMENTAL PROCEDURES
Cell Culture—The ECV 304 cell line (43) was obtained from
“Istituto Zooprofilattico Sperimentale della Lombardia e
dell’Emilia Romagna” (Brescia, Italy), the OVCAR-3 cell line
from human ovarian adenocarcinoma was kindly donated by
Prof. Roberto Taramelli (University of Insubria), and the U937
cell line derived from a human histiocytic lymphoma was a gift
of Carol A. de la Motte (Cleveland Clinic). ECV cells were
grown in EGM2 complete culture medium (Cambrex, Balti-
more, MD) supplemented with 10% fetal bovine serum (FBS),
OVCAR-3 cells were cultured in Dulbecco’s modified Eagle’s
medium (Euroclone) supplemented with 10% FBS, and U937
cells were grown in RPMI 1640 medium (Cambrex) supple-
mented with 5% FBS. Cells were seeded at 2.5  105 cells in
25-cm2 culture flasks and were grown for 96 h in their culture
medium in an atmosphere of humidified 95% air, 5% CO2 at
37 °C.
In some experiments, ECV and OVCAR-3 cells were treated
with 2mM 4-MU (Sigma) or with 2 nM PMA (Sigma) for 18 h of
incubation; with IL-1 (Peprotech) or PDGF-BB (Calbiochem),
both at 10 ng/l, for 18 h; with 200 nM PMA (a non-toxic con-
centration) for 5 or 10 min of incubation; or with IL-1 or
PDGF-BB, both at 10 ng/l, for 5 or 10 min. Further, ECV and
OVCAR-3 cells were incubated for 18 and 24 h with 10 g/ml
tunicamycin from Streptomyces sp. (Sigma), with 10 g/ml
cycloheximide (Sigma), or with 20g/ml suramin (Sigma). The
above mentioned concentrations were chosen from prelimi-
nary experiments in which several doses were tested.
Membrane Fractionation—Membrane fractionations were
done by ultracentrifugation on a discontinuous sucrose gradi-
ent bymodifying previous protocols (44–46). Briefly, cells were
washed with lysis buffer (10 mM Tris, 1.5 mM MgCl2, 10 mM
KCl, pH 7.4) (32) and, subsequently, were incubated with 1 ml
of ice-cold lysis buffer with protease inhibitor mixture (Com-
plete Mini EDTA-free; Roche Applied Science) for 10 min.
After incubation, cells were scraped into the lysis buffer and
disrupted by three strokes of 6 s each at 80%microns amplitude
using a high intensity ultrasonic liquid processor (Sonics &
Materials). The suspensions were left on ice during treatment.
Nuclei were pelleted by spinning at 3,000 rpm for 5min at 4 °C.
The obtained supernatants weremixedwith an equal volume of
85% sucrose (w/v) in 10 mM Tris-HCl, pH 7.5, placed at the
bottomof a discontinuous sucrose concentration gradient (40–
5%) in the same buffer, and centrifuged (150,000 g) for 24 h at
4 °C. After ultracentrifugation, 20 fractions were collected,
starting from the top of the tube. Each fraction was tested for
protein content by the Bradford method and characterized by
Western blot analysis before use.
Western Blotting—Western blot analyses were done to check
the purity of each fraction after membrane purification steps.
Twenty g of proteins were separated by SDS-PAGE, blotted
onto polyvinylidene difluoride membrane (Amersham Bio-
sciences), and probed with polyclonal anti-CD44 monoclonal
antibodies (Sigma), polyclonal anti-glyceraldeyde-3-phosphate
dehydrogenase antibodies (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), polyclonal anti-GM130 (Sigma), and poly-
clonal anti-calnexin (Sigma), as described by Vigetti et al. (47).
Non-radioactive Assay of HA Synthesis—The HAS activity
assaywas essentially developed following themethod described
by Spicer (32) without adding any radiolabeled substrate.
Twenty g of proteins from selected membrane fractions were
mixed with 10 l of 10HA synthase buffer (50 mM DTT, 150
mM MgCl2, 250 mM HEPES, protease inhibitor mixture, pH
7.1). One l of 100 mM UDP-GlcNAc and 1 l of 5 mM UDP-
GlcUA were added and brought to 100 l with lysis buffer with
protease inhibitor mixture. The mixtures composed of mem-
branes and UDP-sugar precursors were incubated for 1 h at
37 °C in a thermomixer.
After incubation, the samples were digested by hyaluroni-
dase SD (Seikagaku Kogyo, Tokyo, Japan) at 37 °C for 1 h at a
concentration of 100milliunits/ml. A 100-milliunit/ml solution
of chondroitinase ABC (Seikagaku Kogyo, Tokyo, Japan) was
then added, and the mixture was incubated at 37 °C for 3 h
Hyaluronan Synthase Activity in Cellular Membranes
OCTOBER 30, 2009•VOLUME 284•NUMBER 44 JOURNAL OF BIOLOGICAL CHEMISTRY 30685
 at UNIV. O
F INSUBRIA, on January 7, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
http://www.jbc.org/content/suppl/2009/09/08/M109.040386.DC1.html
Supplemental Material can be found at:
according to our previous procedure of analysis of HA and CS
(36). Subsequently, SDS (Bio-Rad) was added to each sample at
a final concentration of 1%, and they were heated at 100 °C for 5
min. The samples were then frozen at80 °C and lyophilized.
In some experiments, 2 mM 4-MU or 200 nM PMA, 10 ng/l
IL-1, or 10 ng/l PDGF-BB at final concentrationswere added
into the mixture as controls.
Derivatization andDisaccharideQuantification—The disac-
charides obtained with hyaluronidase SD and chondroitinase
ABC digestions were derivatized with AMAC (Molecular
Probes) and quantified by using PAGEFS, as previously
described by Karousou et al. (36). After the run, gels were
scanned in UV light using a CCD camera and Gel Doc 2000
software (Bio-Rad). Analysis of thedi-nonSHA band was done
by comparison of its migration and intensity with standard
-disaccharides in the same gel. Subsequently, di-nonSHA
quantification in each sample was standardized to total protein
mass. AMAC-derivatized disaccharides were also quantified by
using HPLC (34).
Cell Adhesion Assay—The quantification of leukocyte adhe-
sion was done as described (48) with some modifications.
Briefly, ECVandOVCAR-3 cells were grown to 80% confluence
in 6-well plates and then treated with the test compounds for
18 h. U937 cells were labeled for 1 h at 37 °C with 5 M
CellTrackerTM Green 5-chloromethylflourescein diacetate
(Invitrogen). The labeled cells were washed extensively with
PBS and resuspended at a concentration of 5 106 cells/ml in
RPMImediumwithout FBS. The monocytes were added to the
ECV orOVCAR-3 cells (106/well) and incubated at 4 °C for 1 h.
Nonadherent monocytes were removed by washing the wells
gently at 4 °C with PBS. To verify that cell adhesion was
dependent on HA, we treated some wells with hyaluronidase
SD (2 units/l) or with exogenous added highmolecular weight
HA (4 106 Da; Healon). The quantification of adheredmono-
cytes was done by fluorescence microscopy (Olympus) count-
ing six independent fields.
Immunofluorescence—ECV304 and OVCAR-3 cells grown
on coverslips were rinsed with PBS and fixed in 2% paraform-
aldehyde. The coverslips were preincubated with PBS contain-
ing 2% FBS and then incubated in the same solution containing
biotinylated HA-binding protein (Seikagaku) (5 g/ml) and a
CD44 monoclonal antibody (clone A3D8; 10 g/ml; Sigma)
overnight at 4 °C. The coverslips were washed with PBS and
then incubated with a solution containing fluorescein-tagged
streptavidin (1:500) and CY2.2-conjugated anti-mouse Ig
(HL) (1:1000) in PBS containing 2% FBS. After washing in
PBS, the coverslips were mounted using mounting medium
(Vector Laboratories). The images were obtained using a con-
focal microscope (SP5; Leica). In some experiments, cells were
pretreated with hyaluronidase for 30 min at 37 °C to remove
cell-associated HA, fixed with cold methanol (in order to per-
meabilize the cells), and probed as described above. To inhibit
endocytosis during the hyaluronidase treatment, lower incuba-
tion temperatures were used (i.e. 15 and 25 °C), always obtain-
ing similar results.
Quantitative RT-PCR—Total RNA from both ECV304 and
OVCAR-3 cells was extracted using Tri-reagent solution
(Ambion). To remove DNA contamination, DNase (Ambion)
treatment was done in all samples. One g of total RNA was
retrotranscribed using the High Capacity cDNA synthesis kit
(Applied Biosystems, Foster City, CA) for 2 h at 37 °C. Quanti-
tative RT-PCR was done on an Abi Prism 7000 instrument
(Applied Biosystems) using Taqman Universal PCR Master
Mix (Applied Biosystems). TaqMan gene expression assays
were done for HAS1 (Hs00155410), HAS2 (Hs00193435),
HAS3 (Hs00193436), and -actin (Hs99999903) by amplifica-
tion following the manufacturer’s protocol (Applied Biosys-
tems). Comparison of the amount of each gene transcript
among different samples was made using -actin as the refer-
ence and theCtmethod, as previously described (15, 47, 49).
After treatment with tunicamycin, the presence of ER stress
markers (i.e. CHOP and ATF4) was confirmed by RT-PCR, as
described previously (50).
Statistical Analysis—Statistical analysis of the data was done
using analysis of variance (ANOVA), followed by post hoc tests
(Bonferroni) usingOrigin 7.5 software (Microcal Software, Stu-
dio City, CA).
RESULTS
Measurement of HAS Activity by a Non-radioactive Assay—
Contrary to other GAGs, HA synthesis normally takes place on
the plasma membrane, where active HAS enzymes are located.
HAS proteins are synthesized in the ER, and, through the Golgi
apparatus, they reach the plasma membrane. Previous studies
have indicated that HAS enzymes associated with ER/Golgi
membranes are not active (51), whereas other studies highlight
the presence of HA inside the cells (40, 52) and show that HA
cable structures can arise from internal cell compartments (22).
To investigate the possibility that HAS enzymes associated
with ER/Golgi membranes can synthesize HA, we fractionated
ECV 304 cells (43), which are known to synthesize and secrete
HA into the culture medium, in order to isolate fractions
enriched in plasma membranes, ER/Golgi membranes, and
nuclear membranes. ECV 304 cells are described as a sponta-
neously transformed line derived from human umbilical vein
endothelial cells, although a genetic characterization revealed
that this cell line is not appropriate to study endothelial cell
biology (53).
Among 20 subcellular fractions obtained fromdiscontinuous
sucrose gradient separation (supplemental Fig. S1), we isolated
three fractions representative of plasmamembrane (PM), cyto-
solic membranes (CM), and nuclear membranes (NM). To
check the purity of these representative fractions, we didWest-
ern blot analyses using antibodies against CD44 (a plasma
membrane-specific marker), glyceraldeyde-3-phosphate dehy-
drogenase (a cytosolic membrane marker), GM130 (a Golgi
membrane marker), and calnexin (an ER membrane marker).
Fig. 1A shows that a 90 kDa band corresponding to CD44 was
present only in the PM fraction, indicating that no plasma
membrane protein contaminations were present in the other
two fractions. The 37 kDa band corresponding to the glycer-
aldeyde-3-phosphate dehydrogenase protein was only detected
in the CM fraction. On the other hand, GM130 and calnexin
were present in both the PM and CM fractions but were absent
in theNM fraction. This suggests that the PM fraction contains
some Golgi and ER membrane components.
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Previous studies used radioactive precursors to measure
HAS activity in subcellular fractions (30–34). We recently
showed that PAGEFS and HPLC techniques are simple, sensi-
tive, and low cost procedures to quantify -disaccharides
derived from digested GAGs (36–38). Therefore, we incubated
20 g of proteins contained in PM, CM, and NM fractions and
incubated them at 37 °C for 1 h with 0.05 mM UDP-GlcUA and
1 mM UDP-GlcNAc (final concentrations), as previously
reported for the radioactive HAS activity assay (32). After
enzyme heat inactivation, the samples were digested with hya-
luronidase SD and chondroitinase ABC in order to generate the
-HA and -CS disaccharides, which were then derivatized
with AMAC. The AMAC-disaccharides were separated and
quantified by PAGEFS (Fig. 1B). A specific AMAC-labeled
-HA disaccharide band was identified in the PM and, surpris-
ingly, also in the CM fraction lanes by comparisonwith a stand-
ard mix of disaccharides. Nuclear membranes did not synthe-
size any HA detectable by PAGEFS after incubation with the
UDP-precursors. A control (CNT) shows an analysis of a hya-
luronidase/chondroitinase digest of an equivalent sample of
PM that was incubated without the UDP-sugar substrates and
indicates that endogenous HA contributed minimally to the
amounts generated by the PM and CM samples incubated with
the substrates.
We also quantifiedAMAC-labeled-disaccharides byHPLC
analyses, as shown in Fig. 2. Fig. 2A shows an HPLC analysis to
determine the retention times of a standard mix of disacchar-
ides. Subsequently, we analyzed PM sample disaccharides
before (T 0; Fig. 2B) and after (T 60 min; Fig. 2B) incuba-
tion with the UDP-sugar precursors. The analyses showed a
clear increase of8-fold of theHA disaccharide peak area after
1 h of incubation. Interestingly, the sensitivity of HPLC
revealed that someHAwas present in the PMbefore incubation
with the UDP-sugars, most likely reflecting the presence of HA
localized on the extracellular plasma membrane attached to
HAS enzymes. Similar determinations were done on the CM
fraction (Fig. 2C). The HA disaccharide peak area after 1 h of
incubation with the UDP-sugar precursors increased 3-fold,
indicating that someHA synthetic activity was apparently pres-
ent inside the cell.
The specific HA synthase activities (determined from the
increases between 0 and 60min) were 3.7 103 3.3 104
and 8.4  104  5  104 pmol of -HA/g of membrane
protein/min in the PM fraction and CM fractions, respectively.
Effects of 4-MU, PMA, IL-1, and PDGF-BB on HA Synthesis
Activity—HA synthesis can be modulated by different mole-
cules that can regulate HAS activity. Cells treated with PMA,
IL-1, or PDGF-BB increase the amount of HA released into
the culture medium (29, 54, 55), whereas treating cells with
4-MU decreases synthesis of HA (56). We tested the effects of
these compounds onHAS activity in the PM and CM fractions.
ECV cells were treatedwith 2mM4-MU, 200 nMPMA, 10 ng/l
IL-1, or 10 ng/l PDGF-BB for 5 and 10 min. The three sub-
cellular fractions were then isolated, and 20 g of proteins in
PM and CM fractions were incubated with the UDP-sugar pre-
cursors to quantify the HAS enzymatic activity (Fig. 3). 4-MU
did not inhibit HA synthetic activity in either the PM or CM
fraction, indicating that this compound does not directly inter-
act with HAS proteins, which confirms the finding of Naka-
mura et al. (27). Interestingly, the treatments with PMA, IL-1,
and PDGF-BB increased HAS activity compared with
untreated samples mainly in PM fractions, since the slight
increase in CM fractions was not statistically significant. As a
control, aliquots of the PM fraction from untreated cultures
were exposed to the same concentrations of the reagents in the
presence of the UDP-sugar substrates. In all cases, we detected
no increase in the amount of synthesized HA, indicating that
the reagents did not directly alter HAS activity (data not
shown).
Since PMA, IL-1, and PDGF-BBmodifiedHAS activity only
when added to the viable cells, these findings suggest that some
rapid post-translational modifications are responsible for the
enzymatic activity change. The 5–10-min time frame makes
translational production of new HAS protein unlikely. To
investigate whether HAS phosphorylation could have hap-
pened after cell treatments, we isolated the PM fraction from
cells treated with PMA, IL-1, or PDGF-BB for 5min and incu-
bated themwith or without shrimp alkaline phosphatase (SAP)
beforemeasuringHAS activity. Fig. 4 shows that SAP treatment
significantly reduced HAS activity in each sample except for
FIGURE 1.A, Western blot analyses on PM, CM, andNM fractions isolated after
sucrose gradient cell fractionation by using anti-CD44, anti-glyceraldeyde-3-
phosphate dehydrogenase (GAPDH), anti-GM130, and anti-calnexin antibod-
ies that are plasma membrane, cytosol, Golgi, and ER markers, respectively.
B, PAGEFS analyses of GAGs using the new in vitro non-radioactivemethod to
quantify HAS activity. The STD lane represents 100 pmol of a standard mix of
AMAC-disaccharides. The PM, CM, and NM lanes represent the disaccharide
analyses of GAGs synthesized by 20 g of ECV membrane proteins from PM,
CM, and NM fractions, respectively. Each sample was incubatedwith 0.05mM
UDP-GlcUA and 1mMUDP-GlcNAc at 37 °C for 1 h, followed by hyaluronidase
SD and chondroitinase ABC digestions and AMAC derivatization. The CNT
lane contains 20 g of ECV membrane proteins from PMwithout incubation
with the UDP-sugars. The results shown are representative of three inde-
pendent experiments.
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PDGF-BB-treated cells. The results indicate that phosphoryla-
tion of HAS or of some auxiliary protein that interacts with
HAS after PMA or IL-1 treatment affects HAS enzymatic
activity. Interestingly, PM fractions purified from control cells
and treated with SAP also showed a decreased HAS activity
(Fig. 4), suggesting that the presence of a certain degree of pro-
tein phosphorylation supports HA synthesis without adding
any modulators.
Effect of Tunicamycin on HA Synthesis and Cable Forma-
tion—Tunicamycin inhibits N-glycosylation of proteins and
initiates ER stress (also known as unfolded protein response)
(57), and it is known to modify HA metabolism (23). ECV cell
cultures were treated with 10 g/ml tunicamycin for 18 and
24 h, and ER stresswas confirmed byRT-PCRdetecting specific
markers expressed only in tunicamycin-treated cells (ATF-4
and CHOP) (Fig. 5A). PM and CM fractions were prepared and
tested forHAS activity. Fig. 5B shows that tunicamycin induced
an increase of HAS activity of about 3-fold in the PM fractions
after 18 h of incubation (from about 3.6 103 to about 1.1
102 pmol of HA disaccharide/g of membrane protein/min).
Interestingly, HAS activity in the CM fraction also significantly
increased after 24 h of incubation, reaching the level of that in
PMmembranes. The induction of HAS activity in the fractions
could not be ascribed to an increased HAS translation, because
ER stress drastically reduces protein synthesis (53) and because
we quantifiedmRNAs coding forHASs after tunicamycin treat-
ments by quantitative RT-PCR and found a clear messenger
reduction (result not shown). The HAS activity increment in
the CM fraction was also detected in cells treated with other ER
stress-inducing compounds (i.e. DTT and ethanol), whereas
serum starvation, a nonspecific stress, did not induce ER stress
(supplemental Fig. S2). These data suggest that increased HAS
activity could be a specific response to ER stress.
To confirm that the increased HAS activity was not due to
increased translation of HASmessenger RNAs, ECV cells were
treated with a combination of 10 g/ml tunicamycin and 10
g/ml cycloheximide for 18 h, and the HAS activity was quan-
tified in PM and CM fractions. The combination of cyclohexi-
mide with tunicamycin gave the same results as tunicamycin
treatment alone (Fig. 5C). Moreover, to rule out the possibility
that the increment of HAS activity in the CM fraction could be
due to internalization of plasma membrane-resident HAS
enzymes, ECV cells were treated with a combination of tunica-
mycin and 20g/ml suramin for 18 h, and theHAS activity was
quantified in the PM and CM fractions. Suramin is known to
interfere with internalization, recycling, and degradation of cell
surface proteoglycans (i.e. glypican-1) in the same cell line used
in our experiments (58). We used suramin to attempt to block
HAS protein recycling. Since the commercial HAS antibodies
had poor sensibility in our conditions, to confirm the inhibitory
effect on membrane recycling, we investigated the localization
of CD44 by means of immunofluorescence and confocal
microscopy and found an intensification of plasmamembrane-
associated CD44 signal in cells treated with suramin, support-
ing the inhibition of recycling (supplementary Fig. S3). As
shown in Fig. 5C, suramin in combinationwith tunicamycin did
not alter HAS activity significantly comparedwith tunicamycin
alone in either PM or CM fractions. Neither cycloheximide nor
FIGURE 2.HPLCanalyses of glycosaminoglycans synthesizedusing the in
vitro non-radioactive method to quantify HAS activity. A, 100 pmol of a
standard mix of AMAC-derivatives di-di(2,4)SCS (-disaccharides of chon-
droitin 2,4-sulfated) (I), di-mono4SCS (-disaccharides of chondroitin 4-sul-
fated) (II),di-mono6SCS (-disaccharides of chondroitin 6-sulfated) (III),di-
nonSHA (IV), and di-nonSCS (-disaccharides of CS (non-sulfated)) (V).
B, analysis of HA synthetic activity present in 20 g of PM fraction proteins
before incubation (T 0) and after 1 h of incubation (T 60 min) with UDP-
GlcUA and UDP-GlcNAc after hyaluronidase SD and chondroitinase ABC
digestions and AMAC derivatization. C, analysis of HA synthetic activity pres-
ent in 20g of CM fraction proteins before incubation (T 0) and after 1 h of
incubation (T 60min)withUDP-sugar precursor as in B. The arrows indicate
di-nonSHA peaks in the PM and CM chromatograms. The results shown are
representative of three independent experiments.
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suramin treatment alone increased HA synthesis in PM or CM
fractions compared with untreated cells. An experiment was
done to demonstrate the effects of tunicamycin and suramin in
intact cells. ECV cells were untreated or treated with tunicamy-
cin or tunicamycin plus suramin for 24 h, and the pericellular
HA was removed with hyaluronidase for 30 min at 37 °C. After
fixation with methanol in order to solubilize cell membranes,
the cells were stained forHAand visualized by fluorescence and
confocal microscopy. As shown in Fig. 5D, the green intracel-
lular spots corresponding to HA were clearly increased after
tunicamycin or tunicamycin plus suramin treatments, support-
ing the increased HA synthesis in internal membranes. Since
HA fragments generated by hyaluronidase could increase
endocytosis, we performed control experiments inhibiting
endocytosis by reducing the incuba-
tion temperature (59) and demon-
strating that the intracellular HA
cannot be ascribed to endocytosis of
external HA (result not shown).
There was no apparent change in
CD44 distribution in ECV cells (Fig.
5D) and OVCAR-3 cells (data not
shown) after the tunicamycin
treatments.
Since tunicamycin inhibitsN-gly-
cosylation, we incubated PM and
CM fractions obtained from control
and tunicamycin-treated cells with
N-glycosidase F in order to remove
accessible N-oligosaccharides. In-
terestingly, the removal of N-oligo-
saccharides in PMandCM fractions
prepared from untreated cells significantly increased HAS
activity, whereas such activity remained unvaried in PM and
CM fractions obtained from tunicamycin-treated cells (Fig. 6).
Previous studies have shown that ER stress induces the for-
mation of HA cable-like structures that are adhesive for leuko-
cytes (23) but without describing the molecular mechanism.
Hascall et al. (22) hypothesized that HA cable synthesis could
originate from intracellular compartments. Therefore, we
determined whether the increment of HAS activity in the CM
fraction could be related to HA cable formation. We tested the
adhesion of U937 monocytes to ECV and OVCAR-3 (a cell line
derived from an ovarian cancer (60)) after treatment with 10
g/ml tunicamycin for 18 h. We used these two cell types
because, by quantitative RT-PCR, we found that ECV and
OVCAR-3 expressed different HAS isoform transcripts, HAS3
and HAS2, respectively (results not shown). U937 cells were
marked with a green fluorescent vital dye and added to tunica-
mycin-treated cells. After an incubation of 1 h and the removal
of unbound U937 cells by washing, the monocytes bound to
ECV and OVCAR-3 cells were directly counted under a fluo-
rescent microscope. As shown in Fig. 7A, tunicamycin induced
a strong increase inmonocyte adhesion compared with control
only in the OCVAR-3 cell line. The slight increase in U937
adhesion in tunicamycin treated ECVwas not significant. Inter-
estingly, the interaction of U937 cells with ECV and OVCAR-3
cells was HA-dependent, because hyaluronidase treatment
before adding monocytes inhibited their binding. Moreover,
the addition of exogenous high molecular weight HA (Healon;
average molecular mass 4  106 Da) also strongly inhibited
U937 binding, indicating a competition between cell-derived
HA and exogenously addedHA.A similar adhesion experiment
was done with ECV and OVCAR-3 cells by treating them with
DTT and ethanol. Only OVCAR-3 cells treated with DTT and
ethanol showed an increment of monocyte adhesion, whereas
cells incubated without serum showed results comparable with
the controls (supplemental Fig. S4). Such results suggest that
the U937 cell HA-adhesive properties can be modulated in a
specific manner by the ER stress response, possibly depending
in part on the HAS isoform in the cells.
FIGURE 3. Relative HAS activity in PM (black bars) or CM (white bars) fractions prepared from untreated
ECV cells (controls) or treated for 5 or 10 min with 4-MU (2 mM final concentration), PMA (200 nM final
concentration), IL-1 (10 ng/l final concentration), andPDGF-BB (10 ng/l final concentration). Eighty
percent confluent cells were treated with the compounds cited above for the indicated times, membrane
fractionswereprepared, andHAS activitywas assessedbyusing thenon-radioactivemethodwith PAGEFS and
HPLC analyses. HAS activity is expressed as a percentage relative to control PM. Data represent mean S.E.
from two independent experiments of triplicate determinations.
FIGURE 4.RelativeHAS activity in PMmembrane fraction after SAP treat-
ment. Two hundred nM PMA, 10 ng/l IL-1, and 10 ng/l PDGF-BB were
added to 80% confluent ECV cells. After 10 min of incubation, the ECV mem-
braneswere purified, and 20gof PM fractionproteinswere preincubatedor
not with 0.04 units/l SAP for 30 min and subsequently incubated with the
UDP-precursors and analyzed for HAS activity, as described in the legend to
Fig. 3. *, p 0.01 (ANOVA) without SAP versus with SAP. Values are given as
percentages of the control value without SAP. Data represent mean  S.E.
from two independent experiments of triplicate determinations.
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By using immunofluorescence and confocal microscopy, we
studied the distribution of HA in untreated and tunicamycin-
treated ECV cells cultured for 18 h without finding any cable-
like structures (Fig. 7B). We tried
several combinations of tunicamy-
cin concentrations and incubation
times with the same result (data not
shown). The fluorescence relative to
HA was distributed in a uniform
manner around the cells both in
control and treated cells. In con-
trast, when we treated OVCAR-3
with 10 g/ml of tunicamycin (final
concentration) for 18 h, we found
HA filaments typical of the cable-
like structures (Fig. 7B).
In order to relate HAS activity
and cable formation, we prepared
the subcellular membrane fractions
from untreated and tunicamycin-
treated OVCAR-3 cells and assayed
them for HAS activity, as described
previously. Tunicamycin treatment
induced a significant increase of
HAS-specific activity in the CM
fraction and a significant reduction
of HAS specific activity in the PM
fraction (Fig. 7C), whereas tunica-
mycin-treated ECV cells showed
increased HAS activity in both PM
and CM fractions (Fig. 5C). Experi-
ments with tunicamycin and either
cycloheximide or suramin did not
alter the results with tunicamycin
alone (Fig. 7C), similar to the results
obtained with ECV cells (Fig. 5C).
An experiment was done to demon-
strate the effects of tunicamycin and suramin in intact
OVCAR-3 cells. Cultures were untreated or treated with tuni-
camycin or tunicamycin plus suramin for 24 h, and pericellular
HAwas removedwith hyaluronidase. After fixation withmeth-
anol, HA was stained and visualized by fluorescence and con-
focal microscopy. As shown in supplemental Fig. S5, the green
intracellular spots corresponding to HA were clearly observ-
able after tunicamycin or tunicamycin plus suramin treat-
ments, supporting the increased synthesis of HA in internal
membranes, as was observed in the ECV cells (Fig. 5D).
DISCUSSION
Active HASs normally reside on the plasma membrane,
and their presence in active form in the intracellular com-
partments may represent either the newly synthesized HASs
during the sorting process through ER and Golgi to the
plasma membrane or recycled HASs from the cell surface due
to an endocytic pathway. In this context, the critical issue
is whether the HASs could be active in different cell
compartments.
This study shows the presence of HA synthetic activity both
in plasmamembrane and inmembranes from ER and/or Golgi.
HAS enzymatic activity was quantified in purified membranes
with a new non-radioactive method. In this procedure, we
FIGURE 5. A, RT-PCR amplification of ER stressmarkers (CHOP andATF-4) and housekeeping gene (glyceraldehyde
3-phosphatedehydrogenase;GAPDH) starting fromcDNAobtained fromcontrol (CNT)- and10g/ml tunicamycin
(TN)-treatedECVfor18h.Theresultsarerepresentativeofsix independentexperiments.B, relativeHASactivity inPM
orCMfractionsafterdifferent treatments.EightypercentconfluentECVcellswere leftuntreated (control;whitebars)
or treatedwith a 10g/ml final concentrationof tunicamycin (gray andblack bars). After 18 and24hof incubation,
the ECVmembraneswere purified, and 20g of PMor CM fraction proteins were incubatedwith the UDP-precur-
sors and analyzed for HAS activity, as described previously. *, p 0.01 (ANOVA), treated PM or CM versus control.
Data representmean S.E. from two independent experiments of triplicate determinations.C, 80% confluent ECV
cells were left untreated or treated with 10 g/ml tunicamycin (TN), 10 g/ml cycloheximide (CHX), or 20 g/ml
suramin (SUR) for18h.Membrane fractionswereobtained,andthe relativeHASactivitywascalculatedasdescribed
above. *, p 0.01 (ANOVA), treated PM or CM versus control. Data represent mean S.E. from two independent
experimentsof triplicatedeterminations.D, confocal immunolocalizationofHA(green)andCD44(red)onuntreated,
tunicamycin-treated (10g/ml final concentration), or tunicamycin suramin-treated (20g/ml) ECV pretreated
with hyaluronidase and fixedwithmethanol. Themicrophotographs show representative results of three different
independent experiments.
FIGURE6.RelativeHASactivity inPMorCMfractionsafterdifferent treat-
ments. A, 20 g of PM or CM fraction proteins from control (white bars) or
24-h tunicamycin-treated cells (black bars) were preincubated or not with 3
units/l N-glycosidase F (PNGase; New England Biolabs) for 1 h and assessed
for HAS activity. *, p 0.01 (ANOVA) control without N-glycosidase F versus
other samples. Data represent mean  S.E. from two independent experi-
ments of triplicate determinations.
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added non-radioactive UDP-sugar precursors to the mem-
brane fractions in contrast to previously reportedmethods that
used 14C- or 3H-labeledUDP-precursors (12, 31, 32, 61, 62) and
determined HAS activity by counting radioactivity in newly
synthesized HA. These classical radioactive assays were very
sensitive, but, on the other hand, they involved radioactive
manipulations with all of the problems that this involves. In
order to quantify the newly synthesized HA in our non-ra-
dioactive method, we applied PAGEFS, an electrophoretic
method to measure -disaccharides obtained from digestion
of newly synthesized HA (36). This method requires reduc-
ing end labeling with a fluorophore (AMAC), and the proce-
dure has comparable sensitivity to radioactive methods.
Moreover, since AMAC labels the reducing end of the disac-
charides, it does not label the excess of UDP-sugar precur-
sors, which is an issue with the classical radioactive method.
While we were working on this
project, another method to assay
HAS activity without using radio-
isotopes was developed and pub-
lished (63).
By centrifugation, we prepared
three main fractions containing the
PM, CM, and NM. Although the
PM fraction contained some ER and
Golgi proteins, CM preparations
were negative for plasmamembrane
marker, and the absence of CD44
contaminations in the CM mem-
brane preparation allowed us to
ascribe the cytosolic HAproduction
only to HASs present and active in
the internal membranes of the cells.
The evidence of HAS activity in
cytosol membrane fractions raises
the question of HA synthesis
inside the cells in vivo. In fact, pre-
vious studies (40, 41) described a
significant amount of HA inside
cells, which was proposed to rep-
resent internalization from peri-
cellular HA due to hyaluronidase
activity (40). On the other hand,
other authors (51, 64) proposed
that HASs move throughout the
intracellular membrane organelles
before reaching the plasma mem-
brane, and intracellularHA can rep-
resent the product of HASs located
in ER/Golgi vesicles. Recently it has
been shown that in dividing cells in
hyperglycemic growthmedium, HA
synthesis initiates inside the cell,
which appears to induce autophagy
and extrusion of a monocyte-adhe-
sivematrix (52). It is to be noted that
the observation of intracellular HA
by Evanko and Wight in 1999 was
made in hyperglycemic conditions (40).
Previous studies demonstrated that in various biological sys-
tems, HAS activity could be stimulated with a variety of com-
pounds, such as cyclic AMP, calf serum (65), epidermal growth
factor (66), vanadate (67), PMA (68), insulin-like growth fac-
tor-I (69, 70), PDGF-BB, fibroblast growth factor, and TGF-1
(54). In all reported studies, HAS activity was tested by using a
radioactive approach, and we confirmed such data with our
method. In the case of PMA, IL-1, and PDGF-BB, the mecha-
nisms involved in HAS activation are most likely mediated by
phosphorylation induced by protein kinase C, c-AMP-depend-
ent protein kinases, or calcium ion-dependent protein kinases
(61). The effect of phosphorylation on HAS activity was also
confirmed by our experiments with phosphatases, which dem-
onstrated reduced activity. Only the increased HAS activity
induced by PDGF-BB treatment was found to be resistant to
FIGURE 7. A, U937 adhesion on tunicamycin-treated ECV or OVCAR-3 cells. Eighty percent confluent cells were
left untreated or treated with a 10 g/ml final concentration of tunicamycin. After 18 h of incubation, 1 
106/well fluorescent U937 cells were added for 60 min. After washing with PBS, adherent U937 cells were
counted under a fluorescent microscope, and the number of cells/field is reported. In some experiments,
before adding U937, ECV and OVCAR-3 cells were treated with 2 units/l hyaluronidase for 20 min (Hyal), or
U937 cellswere addedwith 50g/ml highmolecularweightHA (HWHA). *, p 0.05 (ANOVA), untreated versus
treated samples. Data representmean S.E. from two independent experiments of triplicate determinations.
B, confocal immunolocalization of HA (green) and CD44 (red) on untreated or tunicamycin (10 g/ml final
concentration) treated ECV or OVCAR-3 cells. As a control, 2 units/l hyaluronidase was added before the
immunolocalization (Hyal). Themicrophotographs show representative results of three different independent
experiments. The white bars correspond to 25 m. Original magnification was 630. C, 80% confluent
OVCAR-3 cellswere left untreatedor treatedwith 10g/ml tunicamycin (TN), 10g/ml cycloheximide (CHX), or
20 g/ml suramin (SUR) for 18 h. Membrane fractions were obtained, and the relative HAS activities were
calculated as described above. *, p 0.01 (ANOVA), treated PM or CM versus control. Data represent mean
S.E. from two independent experiments of duplicate determinations.
Hyaluronan Synthase Activity in Cellular Membranes
OCTOBER 30, 2009•VOLUME 284•NUMBER 44 JOURNAL OF BIOLOGICAL CHEMISTRY 30691
 at UNIV. O
F INSUBRIA, on January 7, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
http://www.jbc.org/content/suppl/2009/09/08/M109.040386.DC1.html
Supplemental Material can be found at:
phosphatase. This suggests that that the modifications induced
by PDGF-BB could be inaccessible to SAPor reflect an alternate
pathway to activate HAS. Further, our experiments cannot
exclude the possibility that phosphorylation involves other pro-
tein or proteins located in proximity to the HASs that could
have a role in regulating their function after the treatments.
4-MU inhibits HA synthesis by lowering both the cytosolic
concentration of UDP-GlcUA and the expression of HASs (71).
We confirmed that 4-MU reduced HA synthesis in intact cells
(result not shown) without affecting the HAS activity when
added to membrane preparations, as already shown by Naka-
mura et al. (27).
Interestingly, all of the above substances used to treat the
cells for short times drastically modified HA synthetic activity
of HASs on plasma membrane but not that of HASs in the
interior of the cells. In contrast, tunicamycin affected the activ-
ity of both HASs located in the plasma membrane and in
ER/Golgimembranes. The effect of tunicamycin is to induce ER
stress by inhibiting N-glycosylation (57). Protein N-glycosyla-
tion is known to affect protein folding, oligomerization, quality
control, sorting, and transport, moving through ER via the
Golgi complex to their final destination inside and/or outside of
the cells (72). Our data obtained after tunicamycin treatment
suggest that HAS proteins are glycosylated. In fact, the enzy-
matic removal of N-oligosaccharides in proteins isolated from
untreated cells increased HAS activity to levels similar to those
in proteins prepared from tunicamycin-treated cells in which
N-glycosylationwas inhibited by the treatment. It is to be noted
that, as for phosphorylation, N-glycosylation could involve
other not yet identified HAS-regulating proteins.
Tunicamycin treatment requires 18–24 h of incubation to
reach a maximum effect. Although ER stress inhibits protein
synthesis, we used cycloheximide, which inhibits protein syn-
thesis rapidly, and showed that its combination with tunicamy-
cin gave no difference from tunicamycin alone, confirming that
new HAS synthesis does not contribute to the increased HA
synthesis. Moreover, a similar increase of HAS activity in CM
fractions was observed when suramin, an inhibitor of plasma
membrane recycling, was used in combination with tunicamy-
cin, indicating that internalization of HAS enzymes from
plasmamembrane is unlikely to contribute to the increasedHA
synthesis activity in the ER/Golgi membranes. Although sura-
min has been reported to prevent endocytosis of proteoglycans,
the mechanisms involving HA endocytosis may be different.
The fact that CD44 was stopped on the plasma membrane
would suggest that specific internalization of HA is inhibited,
but we cannot exclude the possibility of HA pinocytosis or an
alteration of theHA lysosomal degradation pathway due to sur-
amin treatment.
Cable-like HA structures were described after inducing ER
stress by treating with proinflammatory cytokines both in vitro
and in vivo (73). Such HA structures are adhesive for immune
cells and therefore have a central role in inflammation and
recruitment for monocytes (21). More detailed morphological
analyses suggested that these HA cables seem to have contacts
not only with the surface of the cells where activeHAS enzymes
are located but also with intracellular vesicular structures that
could correspond to Golgi, ER, or the nuclear envelope (22).
Since tunicamycin has been shown to induce HA cable forma-
tion, we tested whether the changes in intracellular HA synthe-
sis could be involved in HA cable formation. As indirect proof
of HA cable formation, we counted the monocytes adherent to
tunicamycin-treated ECV cells but found that the number was
not increased. This suggests that ECV cells did not produce
cables. In contrast, OVCAR-3, a cell line derived from a human
carcinoma strongly increased monocyte adhesion after tunica-
mycin treatment, which suggests that this cell line was able to
synthesize HA cable in our conditions. The direct evidence of
HA cable was obtained by confocal microscopy, which con-
firmed that tunicamycin-stimulated ECV cells did not, whereas
OVCAR-3 cells did, produce HA filaments.
The mechanisms that distinguish the different abilities of
ECV andOVCAR-3 cells to formHA cable structures although
both increase HA synthesis in response to tunicamycin are not
known but are crucial for understanding how the cables are
formed. Our hypothesis is that alteration of HAS activity could
have a role in cable formation, and we found that both cell lines
increased HA synthesis activity in membranes enriched in ER
andGolgimembranes. Interestingly,HAS activity in the plasma
membrane decreased in response to tunicamycin in OVCAR-3
cells, which are able to produceHA cables, but not in ECV cells,
which suggests a more complex synthetic mechanism. On the
other hand, the different expression ofHAS isoforms in the two
cell lines, HAS2 in ECV cells and HAS3 in OVCAR-3 cells,
could have a role in this issue. Interestingly, HAS2 and HAS3
sequence analyses through bioinformatic tools (available on the
World Wide Web) show different N-glycosylation sites that
could have different roles. Such analysis revealed that only
HAS2 has two hypothetical asparagine residues (82 and 178 in
the human HAS2 sequence deposited in the public data base
with accession number NP_005319) that could be N-glycosy-
lated. However, these two residues are in the cytosolic region of
the protein, making them unsuitable for thismodification. This
issue could support the hypothesis that suchmodification does
not happen directly on the HAS enzyme but in other not yet
identified protein(s) that could interact and regulate HAS
activity.
The different properties of HAS enzymes were previously
studied on renal tubular cells showing that overexpression of
HAS3 increased HA cable formation, whereas overexpression
of HAS2 reduced it (73, 74).
In conclusion, by using the new non-radioactive method to
assess HAS activity in vitro, we were able to address the ques-
tion about the HAS activity in Golgi and ER membrane. Our
findings highlighted the role ofN-glycosylation and phosphor-
ylation to modulate HAS activity and the possible involvement
of intracellular HASs in the HA cable formation.
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